RxDoctor Payments Data

Jose Alfonso Padilla

Family Medicine · Miami Beach, FLNPI 1710678768

Payments from drug & device makers

$842in general payments, 2019–2025

Across 30 payments — averaging $28.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endo USA, Inc.$197
  • Viiv Healthcare Company$169
  • Phathom Pharmaceuticals, Inc.$127
  • Sumitomo Pharma America, Inc.$96
  • Lilly USA, LLC$55
  • Exact Sciences$42
  • plus $156 from 7 others

What the payments were for

  • Food & beverage$842100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$842 in reported general payments places this provider in the 60th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$9,461
Medicare patients
83
Services billed
20,088

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron79$47,138
MyrbetriqMirabegron35$29,457
Tadalafil44$4,431
Testosterone Cypionate34$1,987
Tamsulosin Hcl167$1,526
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip32$593
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst30$516
Alfuzosin Hcl ErAlfuzosin Hcl17$423
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav27$292
Oxybutynin Chloride ErOxybutynin Chloride17$259
Ciprofloxacin Hcl37$219
Fluconazole15$158
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim21$84
Finasteride19$61
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen12$57

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$96$47,13879 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →